CEMIP

Across TCGA pan-cancer cohorts, CEMIP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEMIP data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CEMIP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEMIP expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC, PDAC, and GBM are the cancer types where CEMIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	III,IV	0.391	0.868	.022	3	view →
PDAC	DFS	Median	IV	0.234	0.766	.026	3	view →
GBM	OS	Quartile	All	1.000	0.919	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CEMIP–LSCC (OS)

Open the LSCC breakdown →